Related Experiment Videos
Monoaminergic dysfunction in Sjögren-Larsson syndrome
P Wester1, U Bergström, A Brun
1Department of Internal Medicine, University of Umeå, Sweden.
Molecular and Chemical Neuropathology
|August 1, 1991
Summary
Sjögren-Larsson syndrome (SLS) shows specific monoamine dysfunction, particularly a severe dopamine deficit in the putamen. This suggests dopamine agonist therapy may help manage SLS symptoms.
Area of Science:
- Neuroscience
- Biochemistry
- Neuropathology
Background:
- Sjögren-Larsson syndrome (SLS) is a rare genetic disorder.
- Understanding the neurochemical alterations in SLS is crucial for developing effective treatments.
Observation:
- Monoamine and metabolite concentrations were analyzed in subcortical brain nuclei of SLS and control cases.
- Neuropathological examination revealed cell loss in substantia nigra and putamen, and white-matter destruction in SLS.
Findings:
- SLS cases exhibited severe dopamine depletion in the putamen (14% of controls).
- Reduced concentrations of dopamine metabolites (3-MT, HVA) were observed in putamen and other striatal regions.
- Noradrenaline levels were generally decreased, while serotonin levels were increased in SLS cases.
Implications:
- The findings indicate a specific monoaminergic dysfunction in Sjögren-Larsson syndrome.
- Targeting the dopaminergic system with agonists may offer a therapeutic strategy for SLS patients.